Share
array:23 [ "pii" => "S2173578614001358" "issn" => "21735786" "doi" => "10.1016/j.acuroe.2014.09.004" "estado" => "S300" "fechaPublicacion" => "2014-11-01" "aid" => "632" "copyright" => "AEU" "copyrightAnyo" => "2014" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Urol Esp. 2014;38:559-65" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 333 "formatos" => array:3 [ "EPUB" => 7 "HTML" => 182 "PDF" => 144 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0210480614000448" "issn" => "02104806" "doi" => "10.1016/j.acuro.2014.02.007" "estado" => "S300" "fechaPublicacion" => "2014-11-01" "aid" => "632" "copyright" => "AEU" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Urol Esp. 2014;38:559-65" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 449 "formatos" => array:3 [ "EPUB" => 10 "HTML" => 337 "PDF" => 102 ] ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Artículo especial</span>" "titulo" => "Información obligatoria que debe conocer un paciente con cáncer de próstata candidato a vigilancia activa" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "559" "paginaFinal" => "565" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Obligatory Information that a Patient Diagnosed of Prostate Cancer and Candidate for an Active Surveillance Protocol must know" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figura 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1565 "Ancho" => 1602 "Tamanyo" => 110605 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Curva de supervivencia libre de tratamiento activo en los 232 incluidos en VA en nuestro centro.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J. Rubio-Briones, I. Iborra, M. Ramírez, A. Calatrava, A. Collado, J. Casanova, J. Domínguez-Escrig, A. Gómez-Ferrer, J.V. Ricós, J.L. Monrós, R. Dumont, J.A. López-Guerrero, D. Salas, E. Solsona" "autores" => array:14 [ 0 => array:2 [ "nombre" => "J." "apellidos" => "Rubio-Briones" ] 1 => array:2 [ "nombre" => "I." "apellidos" => "Iborra" ] 2 => array:2 [ "nombre" => "M." "apellidos" => "Ramírez" ] 3 => array:2 [ "nombre" => "A." "apellidos" => "Calatrava" ] 4 => array:2 [ "nombre" => "A." "apellidos" => "Collado" ] 5 => array:2 [ "nombre" => "J." "apellidos" => "Casanova" ] 6 => array:2 [ "nombre" => "J." "apellidos" => "Domínguez-Escrig" ] 7 => array:2 [ "nombre" => "A." "apellidos" => "Gómez-Ferrer" ] 8 => array:2 [ "nombre" => "J.V." "apellidos" => "Ricós" ] 9 => array:2 [ "nombre" => "J.L." "apellidos" => "Monrós" ] 10 => array:2 [ "nombre" => "R." "apellidos" => "Dumont" ] 11 => array:2 [ "nombre" => "J.A." "apellidos" => "López-Guerrero" ] 12 => array:2 [ "nombre" => "D." "apellidos" => "Salas" ] 13 => array:2 [ "nombre" => "E." "apellidos" => "Solsona" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2173578614001358" "doi" => "10.1016/j.acuroe.2014.09.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173578614001358?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210480614000448?idApp=UINPBA00004N" "url" => "/02104806/0000003800000009/v1_201410280110/S0210480614000448/v1_201410280110/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2173578614001322" "issn" => "21735786" "doi" => "10.1016/j.acuroe.2014.09.001" "estado" => "S300" "fechaPublicacion" => "2014-11-01" "aid" => "622" "copyright" => "AEU" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Urol Esp. 2014;38:566-70" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 280 "formatos" => array:3 [ "EPUB" => 10 "HTML" => 161 "PDF" => 109 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Diagnostic usefulness of the cytological study of the transport buffer in transrectal prostate core biopsies" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "566" "paginaFinal" => "570" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Utilidad diagnóstica del estudio citológico del tampón de transporte en biopsias por punción prostática transrectal" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 768 "Ancho" => 1500 "Tamanyo" => 212744 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Board of microscopic images obtained in cytological preparations showing: (A) normal monolayer plate of the prostatic epithelium showing the mosaic pattern and sharp edges with tiny intracytoplasmic pigment; (B) hyperplastic prostatic epithelial monolayer plate with sharp edges and dense cellularity; (C) hyperplastic multilayer plate of cohesive basal cells with high core/cytoplasm ratio and sharp edges; (D) normal colonic mucosa; (E) epithelium of the monolayer seminal vesicle with atypia, pigment, and cell detachment; and (F) groups of multilayer neoplastic cells with atypia, cell detachment, and waste (Papanicolaou stain, original magnification, ×400).</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J.I. López, F. Cáceres, A. Pérez, V. Caamaño, G. Larrinaga, D. Lecumberri, A. Arruza" "autores" => array:7 [ 0 => array:2 [ "nombre" => "J.I." "apellidos" => "López" ] 1 => array:2 [ "nombre" => "F." "apellidos" => "Cáceres" ] 2 => array:2 [ "nombre" => "A." "apellidos" => "Pérez" ] 3 => array:2 [ "nombre" => "V." "apellidos" => "Caamaño" ] 4 => array:2 [ "nombre" => "G." "apellidos" => "Larrinaga" ] 5 => array:2 [ "nombre" => "D." "apellidos" => "Lecumberri" ] 6 => array:2 [ "nombre" => "A." "apellidos" => "Arruza" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0210480614000345" "doi" => "10.1016/j.acuro.2014.01.003" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210480614000345?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173578614001322?idApp=UINPBA00004N" "url" => "/21735786/0000003800000009/v1_201410250047/S2173578614001322/v1_201410250047/en/main.assets" ] "en" => array:21 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Special article</span>" "titulo" => "Obligatory information that a patient diagnosed of prostate cancer and candidate for an active surveillance protocol must know" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "559" "paginaFinal" => "565" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "J. Rubio-Briones, I. Iborra, M. Ramírez, A. Calatrava, A. Collado, J. Casanova, J. Domínguez-Escrig, A. Gómez-Ferrer, J.V. Ricós, J.L. Monrós, R. Dumont, J.A. López-Guerrero, D. Salas, E. Solsona" "autores" => array:14 [ 0 => array:4 [ "nombre" => "J." "apellidos" => "Rubio-Briones" "email" => array:1 [ 0 => "jrubio@fivo.org" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "I." "apellidos" => "Iborra" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 2 => array:3 [ "nombre" => "M." "apellidos" => "Ramírez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 3 => array:3 [ "nombre" => "A." "apellidos" => "Calatrava" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 4 => array:3 [ "nombre" => "A." "apellidos" => "Collado" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 5 => array:3 [ "nombre" => "J." "apellidos" => "Casanova" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 6 => array:3 [ "nombre" => "J." "apellidos" => "Domínguez-Escrig" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 7 => array:3 [ "nombre" => "A." "apellidos" => "Gómez-Ferrer" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 8 => array:3 [ "nombre" => "J.V." "apellidos" => "Ricós" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 9 => array:3 [ "nombre" => "J.L." "apellidos" => "Monrós" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 10 => array:3 [ "nombre" => "R." "apellidos" => "Dumont" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 11 => array:3 [ "nombre" => "J.A." "apellidos" => "López-Guerrero" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 12 => array:3 [ "nombre" => "D." "apellidos" => "Salas" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] ] ] 13 => array:3 [ "nombre" => "E." "apellidos" => "Solsona" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] ] "afiliaciones" => array:4 [ 0 => array:3 [ "entidad" => "Servicio de Urología, Instituto Valenciano de Oncología, Valencia, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Anatomía Patológica, Instituto Valenciano de Oncología, Valencia, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Laboratorio de Biología Molecular, Instituto Valenciano de Oncología, Valencia, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Departamento de Salud Pública, Consellería de Sanidad, Generalitat Valenciana, Valencia, Spain" "etiqueta" => "d" "identificador" => "aff0020" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Información obligatoria que debe conocer un paciente con cáncer de próstata candidato a vigilancia activa" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1159 "Ancho" => 1572 "Tamanyo" => 87315 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Evolution in time of the indication of AS in recent years, distinguishing real AS (meets all the current inclusion criteria − in the text) of induced AS (it does not meet some of the current inclusion criteria, but we have chosen AS).</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Overtreatment of prostate cancer (PCa) due to early diagnosis or opportunistic screening<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,2</span></a> is well-known, also in Spain.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a> One of the strategies attempting to counteract such a phenomenon is active surveillance (AS), defined as a wait-and-see approach toward potentially curable low/intermediate-risk PCa, which can be proposed to any patient with a life expectancy >10 years and which involves rigorous clinicopathological control (rebiopsies) until objective progression criteria support the active treatment of that PCa with a curative intent (unlike monitoring until palliative care for the metastatic disease). AS, theoretically feasible at any hospital, is now accepted in the European Clinical Guidelines with a level of evidence of 2a.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Nevertheless, we believe that for this extrapolation to any center to be legitimate, minimum standards should be required regarding quality and knowledge about its casuistry, the quality of pathologists, biopsy standardization (Bx) and regarding its possibilities when faced with a strict surveillance protocol so that results can be reproduced in the literature, which on the other hand are still under investigation and need time judgment.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">AS is an alternative which is gaining more and more importance among urologists and patients (who are increasingly better informed). Our aim in this study was to recapitulate all the information that can be extracted from our own casuistry in an attempt to be able to provide our own information to patients if they choose AS at our center. To that end, we believe that, like any other group offering AS, we should analyze certain data in order to frame and develop an AS program, which given its specificity should not be totally extrapolated from one hospital to another. Therefore, we aimed at: (1) quantifying those patients in our environment who are candidates for AS and getting to know who chooses it, (2) knowing our infrastaging, infragradation and insignificant PCa prediction data, (3) improving our candidate selection criteria for AS and (4) knowing the initial active-therapy-free-survival (ATFS) outcomes and the estimated 5-year global ATFS of our patients included in AS programs in order to be able to provide those data to our future candidates for AS.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Methods</span><p id="par0020" class="elsevierStylePara elsevierViewall">We retrospectively reviewed the databases of the Valencian Institute of Oncology of PCa patients; the database of Bx biopsies, patients who had undergone radical prostatectomy (RP) in the period 1986–2013, patients included in AS programs, patients treated with brachytherapy (BT) and with external radiotherapy (RT). It is important to emphasize that our center does not have any assigned population area and that not all the patients treated there were biopsied at our center, since it is a monographic center of oncology which receives patients from other areas. We have the approval of the Ethics Committee for the implementation of these databases and for retrospectively carrying out this study.<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">1.</span><p id="par0025" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleUnderline">Quantification of patients candidates for AS</span>: we randomly chose a period of one year (October 2010/October 2011) and we descriptively analyzed how many patients were considered candidates for AS, establishing the following criteria: patients included in the low-risk group NCCN<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>Bx with at least 10 cylinders taken<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>≤33% affected cylinders. According to these criteria, we reviewed the patients included in prostate Bxs, AS and RP, BT, RT and cryotherapy databases. All databases were cross-checked to avoid duplications and over-estimations.</p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">2.</span><p id="par0030" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleUnderline">Knowledge of our data on infrastaging, infragradation and indolent PCa prediction</span>: retrospective review of our RP database from 1986 to June 2013 with the same criteria for AS inclusion previously described adding a maximum ceiling of 3 affected cylinders for this purpose.</p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">3.</span><p id="par0035" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleUnderline">Knowledge in our environment of the clinicopathological characteristics which may predict an indolent tumor in a RP specimen</span>: retrospective review of the RP database, excluding those with adjuvant hormonotherapy, which were pT0 or tumors with a tumor volume <0.5<span class="elsevierStyleHsp" style=""></span>cc, and which were used along with a Gleason-specimen score ≤6 and pT2a as a definition for insignificant PCa.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> Tumor volume was recorded in a standardized way since 2007, so to this end we selected 535 patients from April 1, 2007 to January 1, 2012.</p></li><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">4.</span><p id="par0040" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleUnderline">Knowledge of the initial results in our patients included in AS</span>: retro- and prospective review of the database of those patients included in AS. Our current inclusion criteria are inspired by the PRIAS<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a> selection criteria and which we consider, although not exactly the same, the reference standard since they are the most commonly used ones in the literature. These are the following: PSA ≤10<span class="elsevierStyleHsp" style=""></span>ng/ml, Bx Gleason score (Bx-Gl) ≤3<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>3 (we accepted a Bx-Gl score of 3<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>4 in patients over 70 years of age), cT1a-b-c, PSA density (PSAD) <0.20, a maximum of 2 affected cylinders and a Bx of at least 10 cylinders. Patients must have a life expectancy of >10 years, be under 80 years of age at the time of PCa diagnosis and have an intellectual level enabling them to understand the AS protocol and to sign the corresponding informed consent form. Besides, in order to get to know our own reality, and as in many other publications on AS, we also included patients with variables which were different to those mentioned above and who entered AS for various reasons (the patient's desire, comorbidities, the need for initial treatment of another tumor, etc.), a group we referred to as induced AS.</p></li></ul></p><p id="par0045" class="elsevierStylePara elsevierViewall">In the current protocol, we have considered since 2010 the performance of a first confirmation Bx at 6 months after diagnosis guided by previous 1.5-T multiparametric nuclear magnetic resonance imaging in agreement with the patient through a transrectal approach (18 cylinders) or through a transperineal approach with a BT rack (24–32 cylinders) depending on their tolerance to diagnostic Bx, prostate volume and on the findings of multiparametric nuclear magnetic resonance imaging. Follow-up Bxs were performed at 8 months and then every 3 years until the age of 80 or until the occurrence of a medical event which may imply a decrease in life expectancy. All Bxs were analyzed by a uropathologist (AC). The progression criteria were an increase in Bx-Gl (according to inclusion) and >2 positive cylinders.</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Results</span><p id="par0050" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0010"><li class="elsevierStyleListItem" id="lsti0025"><span class="elsevierStyleLabel">1.</span><p id="par0055" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleUnderline">Quantification of patients candidate for AS</span>: of the 199 patients with localized Pca who were referred to or diagnosed at our center during the chosen period, 89 (44.7%) met criteria for being included in AS. For different reasons which are explained further below, only 10 of them (11.2%) chose AS. Twenty-nine of the 145 RPs (20%), 21 of the 53 cases of BT (39.6%) and 5 of the 30 cases of RT (16.6%) performed respectively met criteria for AS. The remaining 24 patients up to 89 correspond to patients who were candidates for observation but were lost during follow-up.</p><p id="par0060" class="elsevierStylePara elsevierViewall">The mean of cylinders taken from candidate patients was 11.8<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>2.1 (range 10–18), the mean PSA was 5.95<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>2.23<span class="elsevierStyleHsp" style=""></span>ng/ml (range 0.73–9.93<span class="elsevierStyleHsp" style=""></span>ng/dl). The mean age was 61.2<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>7.3 years (41–76), and the median 61 years. Regarding age and the choice of AS, there were significant differences between active treatment and AS (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.001), with a higher percentage of patients older than 64 in the AS group than in the active treatment group. There were no significant differences in IPSS score among the patients candidates for AS who chose it (average 11.8<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>7.4) versus those who chose active treatment (7.8<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>5.7), neither in the quality-of-life item (2.8<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>1.7 vs. 2<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>1.5), nor in the IIEF-5 score (16<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>5.8 vs. 16.2<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>8.7) respectively.</p></li><li class="elsevierStyleListItem" id="lsti0030"><span class="elsevierStyleLabel">2.</span><p id="par0065" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleUnderline">Knowledge of our data on infrastaging, infragradation and indolent PCa prediction</span>: out of 1449 RPs, 86 patients (5.9%) pre-surgically belonged to the NCCN low-risk group, had a minimum of 10 cylinders taken at Bx, with <33% of affected cylinders and a maximum of 3 affected cylinders (17 patients), 32 had 2 affected cylinders and 37 only one. Taking into consideration only the 589 RPs performed on low-risk patients, 14.6% of this group would have been candidates for AS. The number would have probably been higher if we had known the number of cylinders taken and affected within the entire series, but this was unknown in 560 patients since this was a historical series which took into account the RPs performed since 1986.</p><p id="par0070" class="elsevierStylePara elsevierViewall"><a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a> shows that 14% of tumors were non-organ-confined tumors, 3 patients (3.5%) were pT3b, that 31.4% were infragraded and that more than half had a clinically significant volume. The mean tumor volume was 1.27<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>1.67<span class="elsevierStyleHsp" style=""></span>cc. Only 6 patients (6.97%) were ≥pT3a<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>Gleason ≥7<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>volume >0.5<span class="elsevierStyleHsp" style=""></span>cc. The mean follow-up of this series of 86 patients was 19.20<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>19.93 months (range 1–68 months). Seven patients out of 86 (8.1%) had biochemical progression (PSA<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>0.4<span class="elsevierStyleHsp" style=""></span>ng/ml) over this period, which implies an estimated biochemical progression-free survival rate of 92.5% at 24 months (CI 95%: 83.8–100%) and of 73.6% at 60 months (52.4–94.8%).</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></li><li class="elsevierStyleListItem" id="lsti0035"><span class="elsevierStyleLabel">3.</span><p id="par0075" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleUnderline">Knowledge in our environment of the clinicopathological characteristics which may predict an insignificant tumor in RP specimen</span>: among the 535 RPs we were able to analyze for this purpose, 69 (12.9%) were specimens with a Gleason score of 3<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>3;<span class="elsevierStyleHsp" style=""></span>cc of tumor volume (study group), 25 of which (4.6%) were pT0. Among the pre-RP variables, there were no differences in age, body mass index, a history of PCa in their families, ASA score nor in the number of cylinders taken when compared to the rest of RPs (control group). <a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a> shows the different pre-RP variables which did show statistically significant differences between the study/control groups.</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0080" class="elsevierStylePara elsevierViewall">We observed that the study patients showed higher prostate volumes and therefore lower PSAD values as compared with the control group. Similarly, a percentage of affected cylinders >33% entails in 97.8% of cases a clinically significant tumor in our series.</p></li><li class="elsevierStyleListItem" id="lsti0040"><span class="elsevierStyleLabel">4.</span><p id="par0085" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleUnderline">Knowledge of the initial results in our patients included in AS</span>: from 1996 to July 2013, we included 232 patients in AS, 111 of whom (47.8%) belonged to the induced AS group. <a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a> shows the growing evolution of the indication for AS over the last few years, preferably at the expense of AS but fulfilling the inclusion criteria (true AS).</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia></li></ul></p><p id="par0090" class="elsevierStylePara elsevierViewall">Out of 232 patients, 148 underwent at least one follow-up Bx, at a median time of 11 months; 76 were negative, 27 were positive with no progression criteria and 45 were positive with progression criteria. Just considering confirmation Bxs (defined as those performed before the year of AS inclusion), those performed in the true AS group reclassified the patient in 22.9% of cases, versus 31% of those included in the induced AS group (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.082). During follow-up, 50 patients (21.6%) were cataloged in pathological progression, with statistically significant differences between the true AS group (17 patients, 14%) and the induced AS group (33 patients, 29.7%) (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.004).</p><p id="par0095" class="elsevierStylePara elsevierViewall">With a mean follow-up of 36<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>39 months (median 23, range 1–232 months), 63 patients (27.1%) were crossed over to active treatment, only 13 of them as a result of the patient's anxiety with no pathological progression. The median ATFS time was 72.7% (CI 95%: 30.9–114.4). <a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a> shows that ATFS at 24 months was 76.4% (69.7–83.1%) whereas it was 58.1% (48.8–67.4%) at 48 months.</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0100" class="elsevierStylePara elsevierViewall">During follow-up, of the 23 patients, 10 (4.3%) died, 8 of them during AS and 2 during hormonotherapy as an active treatment. 90% of deaths occurred in the induced AS group. Therefore, the estimated 5-year overall survival, assessing follow-up time from the beginning of AS until exitus or the end of follow-up, either under AS or active treatment, was 92.8% in our series (CI 95%: 86.7–98.9%), with no statistically significant differences between the true AS and the induced AS groups (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.282). Of the 63 patients who were crossed over to active treatment, only 3 in the induced AS group developed metastatic progression and one died due to tumor progression.</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Discussion</span><p id="par0105" class="elsevierStylePara elsevierViewall">Good medical practice with regard to a patient diagnosed with organ-confined PCa forces the urologist to have a critical understanding of all his therapeutic strategies. Technological or casuistry limitations should be dodged for the sake of the sick and thus justify patient referral to other centers with those services or with a higher casuistry if we really believe that the patient will benefit from that. AS is, nevertheless, a potentially feasible strategy at any center, regardless of its casuistry. However, we think that it is imperative to know several data regarding its implementation at each center in order to be able to deliver the local results of this strategy to any PCa patient candidate for AS.</p><p id="par0110" class="elsevierStylePara elsevierViewall">Our low enrollment rate in AS (11.2%) was calculated over the period from October 2010 to October 2011, but it is biased since in all the cases of patients who were referred from other centers for the performance of RP, BT, RT or cryotherapy at ours, we respected the dispatcher's indications.</p><p id="par0115" class="elsevierStylePara elsevierViewall">This contrasts with the rate close to 50% of diagnosed patients who chose AS<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> in the Swedish branch of the ERSPC, similar to the potential candidates for AS in our country too.<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> However, the increased acceptance of this strategy comes from both the conviction of the professionals involved in PCa and better information on the part of patients, and both <a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a> in our case and the data from other center in our country, which show that in the year 2011 only 17% of the possible candidates for AS chose active treatment,<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a> are irrefutable data regarding the increase in patients who also choose AS in our environment.</p><p id="par0120" class="elsevierStylePara elsevierViewall">The analysis of our RPs performed in possible candidates for AS showed a 14% infrastaging and a 31.4% infragradation; nevertheless, over half had a significant volume taking into consideration the cutoff point of 0.5<span class="elsevierStyleHsp" style=""></span>cc. The criteria for insignificant PCa were established by Stamey in 1993, in incidental PCas, in specimens from 139 cysto-prostatectomies and in patients who therefore had not been derived from screening programs.<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> Thereby, the cutoff point of 0.5<span class="elsevierStyleHsp" style=""></span>cc has been recently questioned and other authors have increased this point to 1.3<span class="elsevierStyleHsp" style=""></span>cc for the index lesion and to 2.5<span class="elsevierStyleHsp" style=""></span>cc of total tumor volume as a reference for clinically insignificant PCa in patients coming from screening programs,<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a> which without any doubt would substantially increase the number of insignificant tumors in our series and would force us to remake many nomograms using a tumor volume of 0.5<span class="elsevierStyleHsp" style=""></span>cc as a cutoff point. In a review carried out by SEARCH of 2062 RPs, among which 398 (19%) were cT1c-2a, PSA ≤10<span class="elsevierStyleHsp" style=""></span>ng/ml, Gleason ≤6 with no more than one or 2 positive cylinders in a Bx as a minimum sextant, 8% of them showed a Gleason score of 4<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>3, 28% had a Gleason score of 3<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>4, 16% were pT3a and 2% were pT3b.<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a> We deem it important to highlight that less than 7% of our patients had the 3 poor prognosis factors and none had a Gleason score ≥4<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>4 in the specimen (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>). Logically, these data depend on the criteria with which AS is contemplated; in an exhaustive revision work of 1070 RPs and of 16 selection criteria for patients candidates for AS, a range between 10.9% and 33.5% of adverse pathology was detected which was dependent on the thoroughness or on the laxness regarding inclusion criteria.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a></p><p id="par0125" class="elsevierStylePara elsevierViewall">With regard to the analysis of clinical factors which may enable us to predict an insignificant PCa in a RP specimen, we ratify the importance of prostate volume and therefore of PSAD and the number of affected cylinders as independent prognostic factors to that end (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>); this has made us consider a maximum of 2 positive cylinders and a PSAD <0.20, this latter variable being of importance in those prostates <60<span class="elsevierStyleHsp" style=""></span>cc where PSA is frequently higher than 10<span class="elsevierStyleHsp" style=""></span>ng/ml. Both PSAD and the fact of having 2 affected cylinders versus only one cylinder have also been independently associated in many series with progression and the need for active treatment.<a class="elsevierStyleCrossRefs" href="#bib0035"><span class="elsevierStyleSup">7,15,16</span></a> With regard to the relevance of the number of affected cylinders, this will directly depend on the number of cylinders taken; we currently consider a minimum of 10–12 cylinders in the first Bx and in the confirmation biopsy we took 18 (transrectal) or 24–32 (transperineal), since it has been proven that in RP specimens the percentage of adverse pathology with 2 positive cylinders is approximately half of that if, instead of 12, 21 cylinders would have been taken,<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">17</span></a> so this fact should be taken into account along with the patient due to the consequences it entails (continue with or quit the AS program) if for instance there are 3 cylinders with a Gleason score of 3<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>3 in the confirmation or follow-up Bxs.</p><p id="par0130" class="elsevierStylePara elsevierViewall">With the same intention to select good candidates for AS, it is well known the importance of the pathologist's sub-specialization in the analysis of prostate Bxs, with a better prognosis for Gleason ≤3<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>3 having been proven when following the recommendations made by the ISUP-2005<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a> when compared to those same pre ISUP-2005 tumors.<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">19</span></a> The results of the AS series with a greater follow-up can only be improved with the best interpretation of the Gleason score recognized from such a consensus, which forces any center to demand its implementation by a uropathologist.</p><p id="par0135" class="elsevierStylePara elsevierViewall">Finally, from the first analysis performed on our patients under AS we are able to inform future patients who follow the statistics from series published in the literature with a greater follow-up,<a class="elsevierStyleCrossRefs" href="#bib0035"><span class="elsevierStyleSup">7,8,20–23</span></a> perhaps with some slightly lower percentages of ATFS influenced by including approximately half of the series with induced AS criteria. We have not observed any case of metastatic progression in the true AS group so far and the percentages of biochemical progression in the group of patients who were crossed over to active treatment was similar to that observed when the latter was applied as the first strategy at our center, as observed in series with a follow-up greater than ours.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a></p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Conclusions</span><p id="par0140" class="elsevierStylePara elsevierViewall">We believe that the percentage of patients candidates for AS who choose it is going to be increased as urologists and patients are better informed on the potential of the PCa they are confronting. We think that a review of the casuistry at every center should be compulsory in order to be able to truthfully inform patients about the profitability of Bx at the center and of whether the infragradation, infrastaging, of insignificant PCa are in line with those in the literature, as a kind of internal audit enabling an AS program with some kind of guarantees. Once these data have been revised, and with standard criteria (PSA ≤10<span class="elsevierStyleHsp" style=""></span>ng/ml, a PSAD ≤0.2, particularly in voluminous prostates, a maximum number of 2 positive cylinders, a Gleason score of ≤3<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>3 and 3<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>4 in patients over 70 years of age and tumors cT1-2a), an AS protocol can be started with certain guarantees for the patient choosing it. With a mean follow-up of around 3 years, we detected a parallel with the most extensive series on AS, so we think that the AS program can continue to be implemented and can include a growing number of patients.</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Funding</span><p id="par0145" class="elsevierStylePara elsevierViewall">This work has been supported by the grants <span class="elsevierStyleGrantNumber" refid="gs1">PI061619</span>, <span class="elsevierStyleGrantNumber" refid="gs1">PI101206</span> from the <span class="elsevierStyleGrantSponsor" id="gs1">Instituto Carlos III</span> (Madrid, Spain), <span class="elsevierStyleGrantNumber" refid="gs2">ACOMP/2009/176</span> from the <span class="elsevierStyleGrantSponsor" id="gs2">Generalitat Valenciana</span>, and by the Aid to Research from Aztra Zéneca, Spain.</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Authorship</span><p id="par0150" class="elsevierStylePara elsevierViewall">All signatory authors of the article claim that they have complied with the ethical responsibilities required and have actively participated in the completion of the manuscript.</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Conflict of interest</span><p id="par0155" class="elsevierStylePara elsevierViewall">The authors declare that they have no conflict of interest.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:14 [ 0 => array:2 [ "identificador" => "xres378195" "titulo" => array:5 [ 0 => "Abstract" 1 => "Objectives" 2 => "Materials and methods" 3 => "Results" 4 => "Conclusions" ] ] 1 => array:2 [ "identificador" => "xpalclavsec357248" "titulo" => "Keywords" ] 2 => array:2 [ "identificador" => "xres378194" "titulo" => array:5 [ 0 => "Resumen" 1 => "Objetivos" 2 => "Material y métodos" 3 => "Resultados" 4 => "Conclusiones" ] ] 3 => array:2 [ "identificador" => "xpalclavsec357247" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:2 [ "identificador" => "sec0010" "titulo" => "Methods" ] 6 => array:2 [ "identificador" => "sec0015" "titulo" => "Results" ] 7 => array:2 [ "identificador" => "sec0020" "titulo" => "Discussion" ] 8 => array:2 [ "identificador" => "sec0025" "titulo" => "Conclusions" ] 9 => array:2 [ "identificador" => "sec0030" "titulo" => "Funding" ] 10 => array:2 [ "identificador" => "sec0035" "titulo" => "Authorship" ] 11 => array:2 [ "identificador" => "sec0040" "titulo" => "Conflict of interest" ] 12 => array:2 [ "identificador" => "xack98567" "titulo" => "Acknowledgements" ] 13 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2014-02-03" "fechaAceptado" => "2014-02-06" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec357248" "palabras" => array:5 [ 0 => "Prostate cancer" 1 => "Active surveillance" 2 => "Prognostic" 3 => "Patients" 4 => "Information" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec357247" "palabras" => array:5 [ 0 => "Cáncer de próstata" 1 => "Vigilancia activa" 2 => "Pronóstico" 3 => "Pacientes" 4 => "Información" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span class="elsevierStyleSectionTitle" id="sect0010">Objectives</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">To know the necessary information to reproduce the results found in the literature on active surveillance (AS) in prostate cancer (PCa) in our own center so that the information would be objective and correctly given to the patients. We have aimed to study the percentage of candidates for AS chosen in our setting, and the data on infrastaging, subgrading and prediction of insignificant PCa, debugging the predictive value of clinical variables to improve our selection criteria and finally to analyze the results of our patients enrolled in AS.</p> <span class="elsevierStyleSectionTitle" id="sect0015">Materials and methods</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">A retro- and prospective review of our databases was performed. A one-year period was analyzed to know AS candidates. Analysis of our radical prostatectomy specimens for infrastaging, subgrading and prediction of insignificant PCa (Epstein's criteria) was made as well as a uni/multivariate analysis of clinical variables in patients with insignificant PCa in the specimen. A prospective validation was performed with overall survival and survival free of active treatment (SFAT) as endpoints in patients enrolled in AS.</p> <span class="elsevierStyleSectionTitle" id="sect0020">Results</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Between October-2010 and October-2011, 44.7% of our PCa were candidates for AS, but only 11.2% chose it. The percentages found for infrastaging, subgrading and prediction of insignificant PCa were 14%, 31.4% and 55.7%, respectively. However, only just 6 patients (6.97%) had ≥pT3a<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>Gleason ≥7<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>volume >0.5<span class="elsevierStyleHsp" style=""></span>cc PCa. The multivariate analysis showed that PSA density and number of affected cores were independent predictors of insignificant PCa. With a mean follow-up of 36<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>39<span class="elsevierStyleHsp" style=""></span>months, 63 out of 232 patients enrolled in AS went on to active treatment (27.1%), with only 13 due to anxiety without pathologic progression. Median time of SFAT was 72.7 months (CI 95% 30.9–114.4). SFAT at 24 months was 76.4% (69.7–83.1%) and at 48 months 58.1% (48.8–67.4%). Only 10 patients died (4.3%), 9 due to causes different of PCa. Estimated overall survival at 5 years was 92.8% (CI 95% 86.7–98.9%).</p> <span class="elsevierStyleSectionTitle" id="sect0025">Conclusions</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">It should be mandatory to have the exact knowledge of the local data of each center in order to objectively inform patients about prostate biopsy efficiency, and if percentages of infrastaging, subgrading and prediction of insignificant PCa are in accordance with the literature. At 3 years, we reproduced the results of the longest series of AS, so we have ascertained that our AS protocol can be implemented with increasingly more patients.</p>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<span class="elsevierStyleSectionTitle" id="sect0035">Objetivos</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Conocer la información necesaria para reproducir los resultados de la literatura en vigilancia activa (VA) en cáncer de próstata (CaP) en nuestro propio centro, de tal forma que dicha información sea objetiva y se le pueda dar al paciente de forma fehaciente. Contemplamos estudiar el porcentaje de pacientes candidatos a VA y que la escogen en nuestro ambiente, los datos de infraestadificación, infragradación y predicción de CaP insignificante, depurar el poder predictivo de distintas variables clínicas para mejorar nuestros criterios de selección y analizar los resultados de nuestros pacientes en VA.</p> <span class="elsevierStyleSectionTitle" id="sect0040">Material y métodos</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Revisión retro y prospectiva de nuestras bases de datos. Se analiza un periodo de un año natural seleccionando posibles candidatos a VA. Análisis de nuestras prostatectomías radicales para conocer las tasas de infraestadificación, infragradación y tasa de CaP insignificante (criterios de Epstein). Análisis uni/multivariado de variables clínicas en pacientes con tumor insignificante en pieza de prostatectomía radical. Valoración prospectiva de supervivencia global y libre de tratamiento activo (SLTA) en pacientes en VA.</p> <span class="elsevierStyleSectionTitle" id="sect0045">Resultados</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Entre octubre de 2010 y octubre de 2011, un 44,7% de los CaP cumplían criterios para ser incluidos en VA, y un 11,2% la escogieron. Nuestros porcentajes de infraestadificación, infragradación y tasa de CaP insignificante fueron 14%; 31,4%; y 55,7% respectivamente, pero solo 6 pacientes (6,97%) tuvieron CaP<span class="elsevierStyleHsp" style=""></span>≥<span class="elsevierStyleHsp" style=""></span>pT3a<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>Gleason<span class="elsevierStyleHsp" style=""></span>≥<span class="elsevierStyleHsp" style=""></span>7<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>volumen<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>0,5<span class="elsevierStyleHsp" style=""></span>cc. En el estudio multivariado para predicción de tumor insignificante, la densidad de PSA y el número de cilindros afectos son factores independientes. Con un seguimiento medio de 36<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>39<span class="elsevierStyleHsp" style=""></span>meses, de 232 incluidos en VA, 63 pacientes pasaron a tratamiento activo (27,1%), solo 13 por ansiedad sin progresión patológica. La mediana del tiempo de SLTA es de 72,7<span class="elsevierStyleHsp" style=""></span>meses (IC 95%: 30,9–114,4). La SLTA a los 24 meses es del 76,4% (69,7–83,1%) y a 48 meses es del 58,1% (48,8–67,4%). Solo 10 pacientes (4,3%) fallecieron, 9 por causa diferente al CaP. La supervivencia global estimada a 5 años es del 92,8% (IC 95%: 86,7–98,9%).</p> <span class="elsevierStyleSectionTitle" id="sect0050">Conclusiones</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">El conocimiento exacto de la casuística de cada centro debería ser obligatorio para informar a los pacientes verazmente de la rentabilidad de la biopsia y de si los porcentajes de infragradación, infraestadificación y de CaP insignificante se adecuan a los de la literatura. A 3 años reproducimos los resultados de las series más longevas de VA, por lo que el programa de VA puede seguir implementándose e incluyendo cada vez a más pacientes.</p>" ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Rubio-Briones J, Iborra I, Ramírez M, Calatrava A, Collado A, Casanova J, et al. Información obligatoria que debe conocer un paciente con cáncer de próstata candidato a vigilancia activa. Actas Urol Esp. 2014;38:559–565.</p>" ] ] "multimedia" => array:4 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1159 "Ancho" => 1572 "Tamanyo" => 87315 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Evolution in time of the indication of AS in recent years, distinguishing real AS (meets all the current inclusion criteria − in the text) of induced AS (it does not meet some of the current inclusion criteria, but we have chosen AS).</p>" ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1553 "Ancho" => 1604 "Tamanyo" => 96854 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Curve of survival free of active treatment in the 232 patients included in AS in our center.</p>" ] ] 2 => array:7 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">pT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">pT0<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>5 (5.8%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≤pT2c<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>69 (80.2%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≥pT3a<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>12 (14%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Gleason \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≤6<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>59(68.6%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>27 (31.4%) 5 Gl patients (4<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>3) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≥8<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Tumor volume \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Not recorded<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>25 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≤0.5<span class="elsevierStyleHsp" style=""></span>cc<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>27 (44.3%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">>0.5<span class="elsevierStyleHsp" style=""></span>cc<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>34 (55.7%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Perineural inf. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Not recorded<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>27 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Yes<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>22 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>37 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab575299.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Anatomopathological results of the radical prostatectomy specimens that met the criteria selected for AS (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>86).</p>" ] ] 3 => array:7 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Study group (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>69) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Control group (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>466) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">p</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Preoperative PSA</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.036 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>≤10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">57 (14.5%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">337 (85.5%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>10–20 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 (11.7%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">91 (88.3%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>≥20 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">38 (100%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="4" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Gleason biopsy</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>≤6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">54 (15.4%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">296 (84.6%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">118 (100%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>≥8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">51 (100%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="4" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">cT</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.024 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>≤T2a \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">49 (10.8%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">403 (89.2%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>≥T2b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">39 (100%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="4" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Prostate volume</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><<span class="elsevierStyleHsp" style=""></span>0.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Mean (SD) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">52.4 (25.64) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">38.8 (20.05) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Median (min–max) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">47.5 (20–143) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">34 (11–150) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="4" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">PSA density</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Mean (SD) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.1 (0.12) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.3 (0.26) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Median (min–max) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.1 (0–0.6) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.2 (0–2.9) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="4" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Percentage of affected cylinders</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>≤33% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">55 (19.1%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">233 (80.9%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>>33% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 (2.2%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">135 (97.8%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab575298.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Clinicopathological variables with differences between the study (insignificant PCa in RP specimen) and control (not insignificant PCa in RP specimen) groups.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:23 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "C.J. Savage" 1 => "H. Lilja" 2 => "A.M. Cronin" 3 => "D. Ulmert" 4 => "A.J. Vickers" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Cancer Epidemiol Biomark Prev" "fecha" => "2010" "volumen" => "19" "paginaInicial" => "1201" "paginaFinal" => "1207" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Optimizing prostate cancer screening: prospective randomized controlled study of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening program" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Rubio-Briones" 1 => "J. Casanova" 2 => "R. Dumont" 3 => "L. Rubio" 4 => "A. Fernandez-Serra" 5 => "I. Casanova-Salas" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.acuro.2013.09.007" "Revista" => array:3 [ "tituloSerie" => "Actas Urol Esp" "fecha" => "2013" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24210656" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "National prostate cancer registry 2010 in Spain" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.M. Cozar" 1 => "B. Miñana" 2 => "F. Gomez-Veiga" 3 => "A. Rodriguez-Antolín" 4 => "H. Villavicencio" 5 => "A. Cantalapiedra" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.acuro.2012.06.006" "Revista" => array:6 [ "tituloSerie" => "Actas Urol Esp" "fecha" => "2013" "volumen" => "37" "paginaInicial" => "12" "paginaFinal" => "19" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23102541" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent-update 2013" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Heidenreich" 1 => "P.J. Bastian" 2 => "J. Bellmunt" 3 => "M. Bolla" 4 => "S. Joniau" 5 => "T. van der Kwast" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.eururo.2013.09.046" "Revista" => array:6 [ "tituloSerie" => "Eur Urol" "fecha" => "2014" "volumen" => "65" "paginaInicial" => "124" "paginaFinal" => "137" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24207135" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Active surveillance for prostate cancer: barriers to widespread adoption" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "G.S. Sandhu" 1 => "G.L. Andriole" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.eururo.2012.06.047" "Revista" => array:6 [ "tituloSerie" => "Eur Urol" "fecha" => "2012" "volumen" => "62" "paginaInicial" => "984" "paginaFinal" => "985" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22770662" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "J.I. Epstein" 1 => "P.C. Walsh" 2 => "M. Carmichael" 3 => "C.B. Brendler" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "JAMA" "fecha" => "1994" "volumen" => "271" "paginaInicial" => "368" "paginaFinal" => "374" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7506797" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Active surveillance for low-risk prostate cancer worldwide: the PRIAS study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Bul" 1 => "X. Zhu" 2 => "R. Valdagni" 3 => "T. Pickles" 4 => "Y. Kakehi" 5 => "A. Rannikko" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.eururo.2012.11.005" "Revista" => array:6 [ "tituloSerie" => "Eur Urol" "fecha" => "2013" "volumen" => "63" "paginaInicial" => "597" "paginaFinal" => "603" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23159452" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Goteborg randomised population-based prostate cancer screening trial" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "R.A. Godtman" 1 => "E. Holmberg" 2 => "A. Khatami" 3 => "J. Stranne" 4 => "J. Hugosson" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.eururo.2012.08.066" "Revista" => array:6 [ "tituloSerie" => "Eur Urol" "fecha" => "2013" "volumen" => "63" "paginaInicial" => "101" "paginaFinal" => "107" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22980443" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Oncological outcomes in patients potentially eligible for active surveillance who underwent radical prostatectomy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Blazquez" 1 => "V. Hernandez" 2 => "E. de la Peña" 3 => "F.J. Diaz" 4 => "M.D. Martin" 5 => "J.M. de la Morena" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.acuro.2013.02.015" "Revista" => array:6 [ "tituloSerie" => "Actas Urol Esp" "fecha" => "2013" "volumen" => "37" "paginaInicial" => "603" "paginaFinal" => "607" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23850164" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Active surveillance in low-risk prostate cancer. Patient acceptance and results" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "V. Hernandez" 1 => "C. Blazquez" 2 => "E. de la Peña" 3 => "E. Perez-Fernandez" 4 => "F.J. Diaz" 5 => "C. Llorente" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.acuro.2013.02.010" "Revista" => array:6 [ "tituloSerie" => "Actas Urol Esp" "fecha" => "2013" "volumen" => "37" "paginaInicial" => "533" "paginaFinal" => "537" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23618513" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "T.A. Stamey" 1 => "F.S. Freiha" 2 => "J.E. McNeal" 3 => "E.A. Redwine" 4 => "A.S. Whittemore" 5 => "H.P. Schmid" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Cancer" "fecha" => "1993" "volumen" => "71" "numero" => "3 Suppl." "paginaInicial" => "933" "paginaFinal" => "938" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7679045" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T. Wolters" 1 => "M.J. Roobol" 2 => "P.J. van Leeuwen" 3 => "R.C. van den Bergh" 4 => "R.F. Hoedemaeker" 5 => "G.J. van Leenders" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.juro.2010.08.082" "Revista" => array:6 [ "tituloSerie" => "J Urol" "fecha" => "2011" "volumen" => "185" "paginaInicial" => "121" "paginaFinal" => "125" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21074212" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C.J. Kane" 1 => "R. Im" 2 => "C.L. Amling" 3 => "J.C. Presti Jr." 4 => "W.J. Aronson" 5 => "M.K. Terris" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.urology.2009.12.073" "Revista" => array:6 [ "tituloSerie" => "Urology" "fecha" => "2010" "volumen" => "76" "paginaInicial" => "695" "paginaFinal" => "700" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20394969" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comprehensive report on prostate cancer misclassification by 16 currently used low-risk and active surveillance criteria" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J.R. Palisaar" 1 => "J. Noldus" 2 => "B. Loppenberg" 3 => "C. von Bodman" 4 => "F. Sommerer" 5 => "T. Eggert" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1464-410X.2012.10935.x" "Revista" => array:7 [ "tituloSerie" => "BJU Int" "fecha" => "2012" "volumen" => "110" "numero" => "6 Pt B" "paginaInicial" => "E172" "paginaFinal" => "E181" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22314081" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L.M. Wong" 1 => "S.M. Alibhai" 2 => "G. Trottier" 3 => "N. Timilshina" 4 => "T. van der Kwast" 5 => "A. Zlotta" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.eururo.2013.04.038" "Revista" => array:2 [ "tituloSerie" => "Eur Urol" "fecha" => "2013" ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "V. Iremashvili" 1 => "M. Manoharan" 2 => "D.L. Rosenberg" 3 => "M.S. Soloway" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1464-410X.2012.11127.x" "Revista" => array:6 [ "tituloSerie" => "BJU Int" "fecha" => "2012" "volumen" => "111" "paginaInicial" => "574" "paginaFinal" => "579" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22564446" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The role of biopsy core number in selecting prostate cancer patients for active surveillance" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G. Ploussard" 1 => "E. Xylinas" 2 => "L. Salomon" 3 => "Y. Allory" 4 => "D. Vordos" 5 => "A. Hoznek" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.eururo.2009.07.053" "Revista" => array:6 [ "tituloSerie" => "Eur Urol" "fecha" => "2009" "volumen" => "56" "paginaInicial" => "891" "paginaFinal" => "898" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19683860" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0090" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "J.I. Epstein" 1 => "W.C. Allsbrook Jr." 2 => "M.B. Amin" 3 => "L.L. Egevad" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Am J Surg Pathol" "fecha" => "2005" "volumen" => "29" "paginaInicial" => "1228" "paginaFinal" => "1242" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16096414" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0095" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Do adenocarcinomas of the prostate with Gleason score (GS)<span class="elsevierStyleHsp" style=""></span>≤<span class="elsevierStyleHsp" style=""></span>6 have the potential to metastasize to lymph nodes?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "H.M. Ross" 1 => "O.N. Kryvenko" 2 => "J.E. Cowan" 3 => "J.P. Simko" 4 => "T.M. Wheeler" 5 => "J.I. Epstein" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/PAS.0b013e3182556dcd" "Revista" => array:6 [ "tituloSerie" => "Am J Surg Pathol" "fecha" => "2012" "volumen" => "36" "paginaInicial" => "1346" "paginaFinal" => "1352" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22531173" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0100" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "L. Klotz" 1 => "L. Zhang" 2 => "A. Lam" 3 => "R. Nam" 4 => "A. Mamedov" 5 => "A. Loblaw" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2009.24.2180" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2009" "volumen" => "28" "paginaInicial" => "126" "paginaFinal" => "131" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19917860" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0105" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Active surveillance for prostate cancer: past, present and future" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "E.A. Singer" 1 => "A. Kaushal" 2 => "B. Turkbey" 3 => "A. Couvillon" 4 => "P.A. Pinto" 5 => "H.L. Parnes" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/CCO.0b013e3283527f99" "Revista" => array:6 [ "tituloSerie" => "Curr Opin Oncol" "fecha" => "2012" "volumen" => "24" "paginaInicial" => "243" "paginaFinal" => "250" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22450149" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0110" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Active surveillance for prostate cancer: a systematic review of the literature" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.A. Dall’Era" 1 => "P.C. Albertsen" 2 => "C. Bangma" 3 => "P.R. Carroll" 4 => "H.B. Carter" 5 => "M.R. Cooperberg" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.eururo.2012.05.072" "Revista" => array:6 [ "tituloSerie" => "Eur Urol" "fecha" => "2012" "volumen" => "62" "paginaInicial" => "976" "paginaFinal" => "983" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22698574" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0115" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Active surveillance for prostate cancer: progress and promise" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "M.R. Cooperberg" 1 => "P.R. Carroll" 2 => "L. Klotz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2011.34.9738" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2011" "volumen" => "29" "paginaInicial" => "3669" "paginaFinal" => "3676" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21825257" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:4 [ "identificador" => "xack98567" "titulo" => "Acknowledgements" "texto" => "<p id="par0165" class="elsevierStylePara elsevierViewall">This work would not have been possible without the technical assistance of the Data Manager of the Department of Urology of the IVO, Vanessa Pérez and the administrative assistance of Amparo Alcina and Martina Alcayde. We thank the Instituto Carlos III de Madrid for their support (PI061619, PI101206) for various studies on prostate cancer which this work has benefited from.</p>" "vista" => "all" ] ] ] "idiomaDefecto" => "en" "url" => "/21735786/0000003800000009/v1_201410250047/S2173578614001358/v1_201410250047/en/main.assets" "Apartado" => array:4 [ "identificador" => "6273" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Special article" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/21735786/0000003800000009/v1_201410250047/S2173578614001358/v1_201410250047/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173578614001358?idApp=UINPBA00004N" ]
